SAN FRANCISCO – Health care venture capital firm Alta Partners recently closed on a $130 million fund to focus on the development of biotherapeutics and technology-enabled health care services. “For more than 20 years, Alta Partners has invested in leading health care companies driving innovation and improving people’s lives,” said Dan Janney, managing director and a founding partner at Alta Partners, in a statement. The new fund will team with health care entrepreneurs to create companies in two primary areas: the application of biotechnologies to cure or radically change disease; and technology-enabled solutions and services that improve the delivery and quality of health care. “Alta Partners has become renowned for its life sciences investments and we will continue to leverage those successes in our new fund,” said Bob More, managing director at Alta Partners, in a statement. “As the health care industry experiences unprecedented change in delivery and payment reform, we see tremendous opportunities to impact health care with improved solutions.” The fund’s initial investors include: Allakos, a biopharmaceutical company; DispatchHealth, a provider of mobile and virtual health care; eGenesis, a life sciences company developing gene editing technology; and Vir Biotechnology, a therapeutic platform.
You are here: / / Alta Partners raises $130M